-
The recent global outbreak of coronavirus disease-19, also known as COVID-19, has infected more than 142 million people worldwide, causing more than 3 million deaths. It has been shown that up to 40% of hospitalized COVID-19 patients may develop ARDS. Although not proven, anti-inflammatory and anti-cytokine treatments are recommended to suppress the cytokine storm that develops in the early stages of the disease.
In this case report, a case of pulmonary aspergillus developed as a complication of treatment for ARDS caused by covid 19 in a 50-year-old male patient will be presented in the light of current literature.
-
-
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Case Report |
| Authors | |
| Project Number | - |
| Early Pub Date | March 18, 2022 |
| Publication Date | March 18, 2022 |
| Submission Date | September 29, 2021 |
| Acceptance Date | January 5, 2022 |
| Published in Issue | Year 2022 Volume: 39 Issue: 2 |

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.